2016;204:200-205. 186. Abumuaileq RR, Abu-Assi E, Raposeiras-Roubin S, et al. Evaluation of SAMe-TT2R2 risk score for predicting the quality of anticoagulation control in a real-world cohort of patients with non- valvular atrial brillation on vitamin-K antagonists. Europace. 2015;17(5):711-717. 187. Kataruka A, Kong X, Haymart B, et al. SAMe-TT2R2 predicts quality of anticoagulation in patients with acute venous thromboembolism: The MAQI2 experience. Vasc Med. 2017;22(3): 197-203. 188. Palareti G, Antonucci E, Lip GY, et al. The SAME-TT2R2 score predicts the quality of anticoagulation control in patients with acute VTE. A real-life inception cohort study. Thromb Haemost. 2016;115(6):1101-1108. 189. Barnes GD, Lucas E, Alexander GC, Goldberger ZD. National trends in ambulatory oral anticoagulant use. Am J Med. 2015;128(12):1300-1305.e1302. 190. Christensen TD, Larsen TB. Precision and accuracy of point-of- care testing coagulometers used for self-testing and self- management of oral anticoagulation therapy. J Thromb Haemost. 2012;10(2):251-260. 191. FDA. Food and Drug Administration. Point of Care PT/INR Devices for Monitoring Warfarin Therapy. https://www.fda.gov/ downloads/MedicalDevices/NewsEvents/WorkshopsConferences/ UCM491546.pdf. Accessed March 12, 2017. 192. Hohnloser SH, Hijazi Z, Thomas L, et al. Ef cacy of apixaban when compared with warfarin in relation to renal function in patients with atrial brillation: insights from the ARISTOTLE trial. Eur Heart J. 2012;33(22):2821-2830. 193. Hohnloser SH, Basic E, Nabauer M. Comparative risk of major bleeding with new oral anticoagulants (NOACs) and phenprocoumon in patients with atrial brillation: a post- marketing surveillance study. Clin Res Cardiol. 2017;106(8): 618-628. 194. Bytzer P, Connolly SJ, Yang S, et al. Analysis of upper gastrointestinal adverse events among patients given dabigatran in the RE-LY trial. Clin Gastroenterol Hepatol. 2013;11(3):246-252. e241-245. 195. Chan PH, Hai JJ, Huang D, et al. Burden of upper gastrointestinal symptoms in patients prescribed dabigatran for stroke prevention. SAGE Open Med. 2016;4:2050312116662414. 196. Ho MH, Ho CW, Cheung E, et al. 